Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
Abstract Head and neck cancer (HNC) has frequently an aggressive course for the development of resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being assessed. Bortezomib is a proteasome inhibitor with anticancer effects. In vitro antitumoral activity of Bortezom...
Guardado en:
Autores principales: | Monica Benvenuto, Sara Ciuffa, Chiara Focaccetti, Diego Sbardella, Sara Fazi, Manuel Scimeca, Grazia Raffaella Tundo, Giovanni Barillari, Maria Segni, Elena Bonanno, Vittorio Manzari, Andrea Modesti, Laura Masuelli, Massimo Coletta, Roberto Bei |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fb341c343f084ed79de8be99b14fac49 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
por: Fabricio de Carvalho, et al.
Publicado: (2011) -
The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
por: Peihua Luo, et al.
Publicado: (2011) -
Bortezomib in autoimmune hemolytic anemia and beyond
por: Raffaella Pasquale, et al.
Publicado: (2021) -
Somatostatin modulates insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in AD.
por: Grazia Tundo, et al.
Publicado: (2012) -
The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells
por: Yasamin Dabiri, et al.
Publicado: (2017)